期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

从抗血小板治疗的剩余风险看临床血小板功能检测和新药研发 被引量：1

下载PDF
导出
摘要 急性冠状动脉综合征（ACS）患者事件后仍处于高凝状态且持续超过1年，抗血小板治疗下仍存在10％的心血管事件残余风险。阿司匹林＋氯吡格雷是目前全球公认的标准化双联抗血小板治疗方案，尽管此治疗策略在不断地规范化，
作者 姜绮霞 梁春
机构地区 上海长征医院心内科
出处 《上海医学》 CAS CSCD 北大核心 2013年第9期742-745,共4页 Shanghai Medical Journal
关键词 抗血小板治疗 血小板功能检测 新药研发 风险 急性冠状动脉综合征 临床 心血管事件 高凝状态
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献16

  • 1GURBEL P A, BLIDEN K P, DICHIARA J, et al. Evalu- ation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study[J]. Circulation, 2007, 115(25): 3156-3164.
  • 2GOROG D A, SWEENY J M, FUSTER V. Antiplatelet drug ' resistance '. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? [J]. Nat Rev Cardiol, 2009, 6(5): 365-373.
  • 3SARAF S, CHRISTOPOULOS C, SALHA I B, et al. Impaired endogenous thrombolysis in acute coronary syn- drome patients predicts cardiovascular death and nonfatal myocardial infarction[J]. J Am Coll Cardiol, 2010, 55(19) : 2107-2115.
  • 4BARK D L Jr, KU D N. Wall shear over high degree stenoses pertinent to atherothrombosis [J]. J Biomech, 2010, 43(15): 2970-2977.
  • 5WIVIOTT S D, BRAUNWALD E, MCCABE C H, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. NEnglJ Med, 2007, 357(20): 2001-2015.
  • 6MONTALESCOT G, WIVIOTT S D, BRAUNWALD E, et al. Prasugrel compared with clopidogrel in patients under- going percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38) : double-blind, randomised controlled trial[J]. Lancet, 2009, 373(9665) 723-731.
  • 7GURBEL P A, BLIDEN K P, BUTLER K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study [J]. Circulation, 2010, 121(10): 1188-1199.
  • 8The Medicines Company. The Medicines Company discon- tinues phase 3 CHAMPION clinical trial program of cangrelor [EB/OL]. May 13, 2009. http://ir, themedici- nescompany, corn/phoenix, zhtml? c = 122204&-P = irol- newsArticle&ID = 1287788&highlight =. Accessed November 7. 20] 1.
  • 9RAO S. A randomized, double-blind, active controlled trial to evaluate intravenous and oral PRT060128 (elinogrel), a selective and reversible P2Y12 receptor inhibitor, vs clopidogrel, as a novel antiplatelet therapy in patients under- going non- urgent percutaneous coronary interventions (INNOVATE-PCI) [C]. European Society of Cardiology Congress,Stockholm, Augus 28-September 1, 2010.
  • 10KOGUSHI M, YOKOHAMA H, KITAMURA S, etal.Effects of E5555, a protease-activated receptor-1 antagonist, on the inflammatory markers in vitro [J]. J Thromb Hae most, 2007, 5 (Suppl 1): Abstract P-M-059.

同被引文献2

引证文献1

二级引证文献5

上海医学
2013年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部